Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001 - PubMed (original) (raw)

Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001

James A Karlowsky et al. Antimicrob Agents Chemother. 2003 May.

Abstract

Longitudinal surveillance of Enterobacteriaceae for antimicrobial susceptibility is important because species of this family are among the most significant and prevalent human pathogens. To estimate rates of in vitro antimicrobial susceptibility among hospitalized patients in the United States, data from The Surveillance Network were studied for 14 agents tested against 10 species of Enterobacteriaceae (n = 384,279) isolated from intensive-care-unit (ICU) patients and non-ICU inpatients from 1998 to 2001. Cumulative susceptibility (percent) data for all species of Enterobacteriaceae isolated from ICU patients and non-ICU inpatients, respectively, were ranked as follows: ampicillin-sulbactam (45.5 and 57.2) << ticarcillin-clavulanate (74.8 and 83.5) < trimethoprim-sulfamethoxazole (87.0 and 84.5) congruent with cefotaxime (82.9 and 92.6) = ceftazidime (82.3 and 91.0) = ceftriaxone (86.5 and 93.9) = piperacillin-tazobactam (83.5 and 90.5) < levofloxacin (89.3 and 90.6) = ciprofloxacin (91.0 and 91.7) < gentamicin (91.8 and 94.3) < cefepime (95.0 and 97.9) < amikacin (98.5 and 99.2) < imipenem (100 and 100) = meropenem (100 and 100). Of those agents studied only susceptibilities to ciprofloxacin (94 to 89%) and levofloxacin (93 to 89%) decreased in a stepwise manner from 1998 to 2001. Decreased fluoroquinolone susceptibility was most pronounced for Escherichia coli, Proteus mirabilis, and Enterobacter cloacae. For all species of Enterobacteriaceae, trimethoprim-sulfamethoxazole resistance was more commonly observed in isolates with a single-drug resistance phenotype while gentamicin and fluoroquinolone resistances were more common in isolates resistant to at least one additional class of antimicrobial agent. Ongoing surveillance of Enterobacteriaceae will be particularly important to monitor changes in fluoroquinolone susceptibility, as well as changes in the prevalence of isolates resistant to multiple classes of antimicrobial agents.

PubMed Disclaimer

Figures

FIG. 1.

Annual antimicrobial susceptibilities of Enterobacteriaceae from 1998 to 2001 for ICU patients and non-ICU inpatients. Open bars, 1998 data; lightly shaded bars, 1999 data; black bars, 2000 data; hatched bars, 2001 data.

FIG. 2.

Coresistance among fluoroquinolone-susceptible and fluoroquinolone-resistant isolates of Enterobacteriaceae in 2001 for ICU patients and non-ICU inpatients. Open bars, levofloxacin susceptible, ICU; lightly shaded bars, levofloxacin resistant, ICU; black bars, levofloxacin susceptible, non-ICU; hatched bars, levofloxacin resistant, non-ICU.

Cited by

High Prevalence of Klebsiella pneumoniae in Greek Meat Products: Detection of Virulence and Antimicrobial Resistance Genes by Molecular Techniques.
Theocharidi NA, Balta I, Houhoula D, Tsantes AG, Lalliotis GP, Polydera AC, Stamatis H, Halvatsiotis P. Theocharidi NA, et al. Foods. 2022 Feb 28;11(5):708. doi: 10.3390/foods11050708. Foods. 2022. PMID: 35267341 Free PMC article.
Alternative and Complementary Therapies against Foodborne Salmonella Infections.
Ghaly MF, Nasr ZM, Abousaty AI, Seadawy HG, Shaheen MAA, Albogami S, Al-Sanea MM, Bendary MM. Ghaly MF, et al. Antibiotics (Basel). 2021 Nov 26;10(12):1453. doi: 10.3390/antibiotics10121453. Antibiotics (Basel). 2021. PMID: 34943665 Free PMC article.
Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Enterobacterales Bacteremia.
Huang HY, Wang CF, Lu PL, Tseng SP, Wang YL, Chen TC, Chang K, Tu HP, Lin SY. Huang HY, et al. Antimicrob Agents Chemother. 2021 May 18;65(6):e00074-21. doi: 10.1128/AAC.00074-21. Print 2021 May 18. Antimicrob Agents Chemother. 2021. PMID: 33782006 Free PMC article.
Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan.
Nakano R, Nakano A, Abe M, Nagano N, Asahara M, Furukawa T, Ono Y, Yano H, Okamoto R. Nakano R, et al. Heliyon. 2019 Mar 2;5(3):e01291. doi: 10.1016/j.heliyon.2019.e01291. eCollection 2019 Mar. Heliyon. 2019. PMID: 30886932 Free PMC article.

References

1. Acar, J. F., and F. W. Goldstein. 1998. Consequences of increasing resistance to antimicrobial agents. Clin. Infect. Dis. 27(Suppl. 1):S125-S130. - PubMed
1. Blumberg, H. M., D. Rimland, D. J. Carroll, P. Terry, and I. K. Wachsmuth. 1991. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J. Infect. Dis. 163:1279-1285. - PubMed
1. Bradford, P. A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951. - PMC - PubMed
1. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233. - PMC - PubMed
1. Cosgrove, S. E., K. S. Kaye, G. M. Eliopoulos, and Y. Carmeli. 2002. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med. 162:185-190. - PubMed

Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001 - PubMed (original) (raw)